» Articles » PMID: 33757943

Trends in Known and Undiagnosed Diabetes, HbA1c Levels, Cardiometabolic Risk Factors and Diabetes Treatment Target Achievement in Repeated Cross-sectional Surveys: the Population-based Tromsø Study 1994-2016

Overview
Journal BMJ Open
Specialty General Medicine
Date 2021 Mar 24
PMID 33757943
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim of this study was to investigate time trends in known and undiagnosed diabetes, glycated haemoglobin (HbA1c) levels and other cardiometabolic risk factors in the general population as well as treatment target achievement among those with diabetes.

Design And Setting: Repeated cross-sectional surveys in the population-based Tromsø Study.

Methods: We used age-adjusted generalised estimating equation models to study trends in self-reported and undiagnosed (HbA1c ≥6.5%) diabetes, cardiometabolic risk factors and the metabolic syndrome in 27 281 women and men aged 40-84 years examined in up to four surveys of the Tromsø Study between 1994 and 2016. Further, we analysed trends in diabetes treatment target achievement.

Results: During 1994-2016, diabetes prevalence increased in women (2.3% to 4.6%) and men (2.4% to 5.8%) and in all age groups, while the proportion of undiagnosed diabetes in women (32% to 17%) and men (37% to 24%) decreased. Blood pressure and total cholesterol decreased, while waist circumference increased in participants with and without diabetes, leading to a relatively stable prevalence of the metabolic syndrome throughout the study period. There was a marginal increase in HbA1c levels among participants without diabetes. Only half of those with diabetes achieved the treatment target of HbA1c ≤7.0%.

Conclusion: In the last two decades, diabetes prevalence increased, while the proportion of undiagnosed diabetes declined. The prevalence of the metabolic syndrome remained stable throughout, driven by opposing trends with an increase in obesity and a decrease in other cardiometabolic risk factors. HbA1c treatment target achievement did not improve.

Citing Articles

Association of C-reactive protein with future development of diabetes: a population-based 7-year cohort study among Norwegian adults aged 30 and older in the Tromsø Study 2007-2016.

Tong K, Hopstock L, Cook S BMJ Open. 2023; 13(9):e070284.

PMID: 37775289 PMC: 10546179. DOI: 10.1136/bmjopen-2022-070284.


Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial.

Shestakova M, Kvasnikov B, Erina E, Isachenko E, Andreev A BMJ Open Diabetes Res Care. 2023; 11(3).

PMID: 37328272 PMC: 10277051. DOI: 10.1136/bmjdrc-2022-003290.


Longitudinal changes in vitamin D concentrations and the association with type 2 diabetes mellitus: the Tromsø Study.

Allaoui G, Rylander C, Fuskevag O, Averina M, Wilsgaard T, Brustad M Acta Diabetol. 2022; 60(2):293-304.

PMID: 36456716 PMC: 9852201. DOI: 10.1007/s00592-022-02001-y.


The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population.

Malyutina S, Mazurenko E, Mazdorova E, Shapkina M, Avdeeva E, Mustafina S J Pers Med. 2022; 12(10).

PMID: 36294828 PMC: 9604909. DOI: 10.3390/jpm12101689.


The seventh survey of the Tromsø Study (Tromsø7) 2015-2016: study design, data collection, attendance, and prevalence of risk factors and disease in a multipurpose population-based health survey.

Hopstock L, Grimsgaard S, Johansen H, Kanstad K, Wilsgaard T, Eggen A Scand J Public Health. 2022; 50(7):919-929.

PMID: 35509230 PMC: 9578102. DOI: 10.1177/14034948221092294.


References
1.
. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7):1327-34. PMC: 2699715. DOI: 10.2337/dc09-9033. View

2.
Jorgensen M, Ellervik C, Ekholm O, Johansen N, Carstensen B . Estimates of prediabetes and undiagnosed type 2 diabetes in Denmark: The end of an epidemic or a diagnostic artefact?. Scand J Public Health. 2018; 48(1):106-112. DOI: 10.1177/1403494818799606. View

3.
Hopstock L, Bonaa K, Eggen A, Grimsgaard S, Jacobsen B, Lochen M . Longitudinal and secular trends in total cholesterol levels and impact of lipid-lowering drug use among Norwegian women and men born in 1905-1977 in the population-based Tromsø Study 1979-2016. BMJ Open. 2017; 7(8):e015001. PMC: 5724161. DOI: 10.1136/bmjopen-2016-015001. View

4.
Claudi T, Midthjell K, Furuset K, Hanssen K, Hestvold P, Ogar P . [The NSAM (Norwegian Society of General Practitioners) treatment program for diabetes in general practice]. Tidsskr Nor Laegeforen. 1995; 115(18):2301-2. View

5.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View